Allergan plc is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan’s development programs in Gastroenterology are focused on advancing new treatments in ulcerative colitis, Crohn’s disease, NASH and diabetic gastroparesis.

Members from the biostatistics team with expertise in study protocol and statistical analysis planning and the clinical development department with expertise in non-alcoholic steatohepatitis (NASH) will carry out the work on EUPEARL, specifically in Work Packages 2 and 6, respectively.

Allergan is actively developing treatments for NASH and associated liver fibrosis, with late stage compound in Phase 3 development. Allergan will serve as the EFPIA Co-Lead for DSWP6, NASH, based on the contributors’ experience with NASH literature gaps, protocol development and regulatory experience.